DE60042168D1 - Chronotherapeutische diltiazem formulierungen und deren verabreichung - Google Patents
Chronotherapeutische diltiazem formulierungen und deren verabreichungInfo
- Publication number
- DE60042168D1 DE60042168D1 DE60042168T DE60042168T DE60042168D1 DE 60042168 D1 DE60042168 D1 DE 60042168D1 DE 60042168 T DE60042168 T DE 60042168T DE 60042168 T DE60042168 T DE 60042168T DE 60042168 D1 DE60042168 D1 DE 60042168D1
- Authority
- DE
- Germany
- Prior art keywords
- diltiazem
- given
- administration
- hours
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 title abstract 7
- 229960004166 diltiazem Drugs 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002292247A CA2292247A1 (en) | 1999-12-10 | 1999-12-10 | Chronotherapeutic formulations of diltiazem and the administration thereof |
US46533899A | 1999-12-17 | 1999-12-17 | |
CA002307547A CA2307547C (en) | 1999-12-10 | 2000-05-04 | Chronotherapeutic diltiazem formulations and the administration thereof |
US09/567,451 US7108866B1 (en) | 1999-12-10 | 2000-05-08 | Chronotherapeutic diltiazem formulations and the administration thereof |
PCT/CA2000/000593 WO2001041744A1 (en) | 1999-12-10 | 2000-05-23 | Chronotherapeutic diltiazem formulations and the administration thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60042168D1 true DE60042168D1 (de) | 2009-06-18 |
Family
ID=27427563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60042168T Expired - Lifetime DE60042168D1 (de) | 1999-12-10 | 2000-05-23 | Chronotherapeutische diltiazem formulierungen und deren verabreichung |
Country Status (8)
Country | Link |
---|---|
US (1) | US7108866B1 (de) |
EP (1) | EP1235562B1 (de) |
JP (1) | JP2003516347A (de) |
AT (1) | ATE430561T1 (de) |
AU (1) | AU4903700A (de) |
DE (1) | DE60042168D1 (de) |
ES (1) | ES2325826T3 (de) |
WO (1) | WO2001041744A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
US6620439B1 (en) | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
US20040029959A1 (en) * | 2002-08-08 | 2004-02-12 | John Devane | Isosorbide mononitrate compositions and methods of their use |
CA2496837A1 (en) * | 2002-09-09 | 2004-03-18 | Biovail Laboratories Inc. | Chronotherapeutic diltiazem formulations and the administration thereof |
US8778395B2 (en) | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
US20090136550A1 (en) * | 2007-11-16 | 2009-05-28 | Capricorn Pharma Inc. | Modified release formulations of diltiazem |
JP2011524891A (ja) * | 2008-06-19 | 2011-09-08 | ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルク | 時間治療的医薬剤形 |
JP5714600B2 (ja) | 2009-12-18 | 2015-05-07 | フリースランドカンピナ・ネーデルランド・ホールディング・ビー.ブイ.FrieslandCampina Nederland Holding B.V. | 共加工された錠用賦形剤混合物、その調製及び使用 |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
SG193587A1 (en) | 2011-03-23 | 2013-10-30 | Ironshore Pharmaceuticals & Dev Inc | Methods and compositions for treatment of attention deficit disorder |
WO2023025672A1 (en) | 2021-08-25 | 2023-03-02 | Basf Se | Direct tableting auxiliary composition |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7813246L (sv) | 1978-12-22 | 1980-06-23 | Haessle Ab | Fast farmaceutisk beredning innehallande kroppar med flera ytskikt |
FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
JPS58208222A (ja) | 1982-05-28 | 1983-12-03 | Japan Found Cancer | 抗腫瘍剤効果増強剤 |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IE56999B1 (en) | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5002776A (en) | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4917899A (en) | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
EP0164669B1 (de) | 1984-06-13 | 1991-01-23 | Röhm Gmbh | Verfahren zum Überziehen von Arzneiformen |
SE8404467D0 (sv) | 1984-09-06 | 1984-09-06 | Ferrosan Ab | Controlled-release medical preparations |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4600645A (en) | 1985-01-31 | 1986-07-15 | Warner-Lambert Company | Process for treating dosage forms |
GB8521494D0 (en) | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
LU86077A1 (fr) | 1985-09-18 | 1987-04-02 | Pharlyse Sa | Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques |
LU86099A1 (fr) | 1985-09-30 | 1987-04-02 | Pharlyse | Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4696924A (en) | 1986-01-10 | 1987-09-29 | Warner-Lambert Company | Method for using diltiazem for treating stroke |
US4753802A (en) | 1986-03-19 | 1988-06-28 | Alza Corporation | Verapamil dosage form |
ES2038669T3 (es) | 1986-09-18 | 1993-08-01 | London School Of Pharmacy Innovations Ltd | Formulacion farmaceutica. |
IT1200217B (it) | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
DK173505B1 (da) * | 1987-02-20 | 2001-01-15 | Pharmatec Internat S R L | Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t |
US5622716A (en) | 1987-02-20 | 1997-04-22 | Farmarc Nederland B.V. | Process for preparing a retard product containing diltiazem for a single daily administration |
US4808413A (en) | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4880631A (en) | 1987-09-24 | 1989-11-14 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US5219621A (en) | 1987-10-16 | 1993-06-15 | Elan Corporation, Plc | Methods of treatment with diltiazem formulations |
US5336504A (en) | 1987-10-16 | 1994-08-09 | Elan Corporation, Plc | Diltiazem formulations and methods of treatment |
NZ226575A (en) * | 1987-10-16 | 1991-01-29 | Elan Corp Plc | Controlled release formulation containing cis-(+)-3-acetyloxy-5-(2-(dimethylamino)ethyl)-2,3 dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepine-4(5h)one(diltiazem) and having a surrounding membrane |
GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
FR2623714B1 (fr) | 1987-11-26 | 1990-04-20 | Ethypharm Sa | Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu |
FR2624732B1 (fr) | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
IT1216570B (it) | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
US5344657A (en) | 1988-04-27 | 1994-09-06 | Elf Sanofi | Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them |
US5468755A (en) | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
US5731287A (en) | 1988-05-10 | 1998-03-24 | Louisiana State University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates |
US5585347A (en) | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
US4859470A (en) | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
US4966769A (en) | 1988-06-02 | 1990-10-30 | Alza Corporation | Method for delivering dosage form for diltiazem |
GB8820353D0 (en) | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5000962A (en) | 1989-08-25 | 1991-03-19 | Schering Corporation | Long acting diltiazem formulation |
IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5175003A (en) | 1990-04-06 | 1992-12-29 | Biosytes Usa, Inc. | Dual mechanism controlled release system for drug dosage forms |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5208037A (en) | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
US5288505A (en) | 1991-06-26 | 1994-02-22 | Galephar P.R., Inc., Ltd. | Extended release form of diltiazem |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
US5843347A (en) | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5558879A (en) | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
US5626860A (en) | 1995-06-07 | 1997-05-06 | The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College | Method for regulating metabolism with dopamine beta hydroxylase inhibitors |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5830503A (en) | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US5851555A (en) | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
-
2000
- 2000-05-08 US US09/567,451 patent/US7108866B1/en not_active Expired - Lifetime
- 2000-05-23 ES ES00930909T patent/ES2325826T3/es not_active Expired - Lifetime
- 2000-05-23 EP EP00930909A patent/EP1235562B1/de not_active Expired - Lifetime
- 2000-05-23 DE DE60042168T patent/DE60042168D1/de not_active Expired - Lifetime
- 2000-05-23 AU AU49037/00A patent/AU4903700A/en not_active Abandoned
- 2000-05-23 JP JP2001543089A patent/JP2003516347A/ja active Pending
- 2000-05-23 AT AT00930909T patent/ATE430561T1/de not_active IP Right Cessation
- 2000-05-23 WO PCT/CA2000/000593 patent/WO2001041744A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ATE430561T1 (de) | 2009-05-15 |
EP1235562B1 (de) | 2009-05-06 |
EP1235562A1 (de) | 2002-09-04 |
WO2001041744A1 (en) | 2001-06-14 |
US7108866B1 (en) | 2006-09-19 |
AU4903700A (en) | 2001-06-18 |
ES2325826T3 (es) | 2009-09-21 |
JP2003516347A (ja) | 2003-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60042168D1 (de) | Chronotherapeutische diltiazem formulierungen und deren verabreichung | |
NO20022014D0 (no) | Kontrollert frigjöring av hydrocodone formuleringer | |
BR0014383A (pt) | Composições de liberação controlada compreendendo nimesulida | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
FR2811571B1 (fr) | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif | |
ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
IE871981L (en) | Programmed release formulation. | |
HUP0104039A2 (hu) | Módosított hatóanyagleadású sokszemcsés készítmény | |
IL96900A0 (en) | Pharmaceutical composition containing naproxen | |
NO975872D0 (no) | Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter | |
AU2766689A (en) | New pharmaceutical formulations with programmed release | |
ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
CO5060477A1 (es) | Forma de dosificacion de nefazodona | |
RU2003100507A (ru) | Фармацевтические композиции | |
HUP0401429A2 (hu) | Lumirakoxibot tartalmazó gyógyszerkészítmény | |
BR0207297A (pt) | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo | |
WO2003099214A3 (en) | Biguanide formulations | |
HRP20020258B1 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
CA2307547A1 (en) | Chronotherapeutic diltiazem formulations and the administration thereof | |
RS20060413A (en) | Non-disintegrating oral solid composition of high dose of water soluble drugs | |
IT1293835B1 (it) | Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione | |
TH76767A (th) | สูตรผสมทางเภสัชกรรมของ 5,7,14-ไทรอะซาเตตระไซโคล[10.3.1.02,11.04,9]-เฮกซะเดคะ-2(11),3,5,7,9-เพนทาอีน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R082 | Change of representative |
Ref document number: 1235562 Country of ref document: EP Representative=s name: UEXKUELL & STOLBERG, DE |
|
R081 | Change of applicant/patentee |
Ref document number: 1235562 Country of ref document: EP Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL, BB Free format text: FORMER OWNER: BIOVAIL LABORATORIES INTERNATIONAL S.R.L., COLLYMORE ROCK, BB Effective date: 20121017 |
|
R082 | Change of representative |
Ref document number: 1235562 Country of ref document: EP Representative=s name: UEXKUELL & STOLBERG, DE Effective date: 20121017 |